Cerebellar imaging markers to predict antipsychotic response in first-episode psychosis
Official title: Cerebellar-cortical Circuitry and Prediction of Treatment Response in Early Psychosis
Run by Northwell Health · NCT07483294 · Data updated 2026-11-12
This will test whether cerebellar brain scans can predict how people with first-episode psychosis respond to 12 weeks of treatment with risperidone or aripiprazole.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 15 Years to 40 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Northwell Health Academic / other |
| Locations | 1 site (Glen Oaks, New York) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | December 1, 2029 |
| Study ends | June 1, 2030 |
| Registry record updated | May 26, 2026 |
| Trial ID | NCT07483294 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 16–40 with a first-episode psychotic disorder, moderate positive symptoms on the BPRS, antipsychotic exposure of eight weeks or less, and capacity to provide informed consent.
✕Probably not a fit
Patients with chronic or long-standing psychosis, serious neurological or endocrine disorders, active suicidal or homicidal risk, inability to complete MRI or clinical assessments, or who require medications with psychotropic effects are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study will recruit 120 participants aged 16–40 with a first-episode psychotic disorder who have received eight weeks or less of antipsychotic treatment. Participants receive naturalistic clinical care with either risperidone or aripiprazole for 12 weeks while comprehensive clinical ratings and neuroimaging focused on cerebellar-cortical circuitry are collected at baseline and after treatment. Imaging and clinical data will be analyzed to identify cerebellar structural or connectivity markers that correlate with symptom response. The approach seeks biomarkers usable under standard-care conditions to inform individualized treatment choices.
Why it matters
Potential benefit: If successful, this could help clinicians choose the most effective antipsychotic sooner by using cerebellar imaging to guide treatment and reduce trial-and-error.
How similar studies have gone: Some prior neuroimaging studies have linked brain connectivity measures to antipsychotic response, but cerebellum-centered biomarkers are relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of a first-episode psychotic disorder including: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, psychotic disorder Not Otherwise Specified (NOS), bipolar disorder with psychosis, and major depressive disorder with psychosis; * Current positive symptoms rated \> 3 (moderate) on one or more of the Brief Psychiatric Rating Scale (BPRS) psychosis items: conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought content; * At early phase of illness as defined by having taken antipsychotic drugs for a cumulative lifetime period of 8 weeks or less; * Age 15 to 40; * Competent to sign informed consent. Exclusion Criteria: * Serious neurological or endocrine disorder or brain trauma; * Any medical condition which requires treatment with a medication with psychotropic effects; * Significant risk of suicidal or homicidal behavior; * Cognitive or language limitations, or any other factor that would preclude subjects providing informed consent; * Contraindications to antipsychotic monotherapy; * Contraindications to MR imaging (e.g. pacemaker); * Pregnancy by self report.
Where it's running
-
Zucker Hillside Hospital
Glen Oaks, New York, United States Recruiting
Study contacts
- Study coordinator: Hengyi Cao
- Email: hcao2@northwell.edu
- Phone: 718-470-5913
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
State Representation in Early Psychosis 2
This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.
-
Recovery-oriented suicide prevention for young people at clinical high risk for psychosis
This program tests a peer-supported, clinician-led suicide prevention group for young people at clinical high risk for psychosis to see if it helps reduce suicidal thoughts and support recovery.
-
Combined brain stimulation and yoga for improving cognition in psychosis
This study tests whether active brain stimulation plus yoga can improve thinking skills and daily function in adults with psychosis.
-
See if an early-detection program reduces time to treatment for first-episode psychosis
We test whether a large, region-wide early-detection program can shorten the time from first psychotic symptoms to treatment and help people function better later.
-
The Mouth Matters in Mental Health Trial –2
This trial tests whether a link work program helps adults with severe mental illness to attend routine dental appointments and improves their oral health-related quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.